47 results
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including share option … ”) to which the Company and the Manager may be
subject in such proportion as is appropriate to reflect the relative benefits received by the Company
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
that we are subject to the HFCA Act, as the same may be amended, you may be deprived of the benefits of such inspection which could result … in China, you may be deprived of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
benefits
Share-based payments
The Company accounts for share-based compensation in accordance with IFRS 2 “Share-based payment” (“IFRS 2”), which … substantially all of the economic benefits from the use of the identified asset throughout the period of use; and
we have the right to direct the use
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Current report (foreign)
4:06pm
pensions, health insurance, death or sickness benefits, whether to the Director or to any other person connected to or related to him.
16.16 Unless his … fellow Directors determine otherwise, a Director is not accountable to the Company for remuneration or other benefits received from any other company
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
be deprived of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital markets and trading of our … is not able to fully conduct inspections of our auditor’s work papers in China, you may be deprived of the benefits of such inspection which could result
F-3
c5y5b etxx9
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.4
mgmh6kz4rv3179b0aah5
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.3
ln9a0x4xzyt
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-10.1
427g fcjy1m747
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-99.1
8rw mmhdlivrb135yz
4 May 23
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
7:56am
424B3
dwhmc80tgh
31 Mar 23
Prospectus supplement
4:04pm
424B3
iul64d94ij0w6c
2 Dec 22
Prospectus supplement
4:17pm
F-1
zn0tvmnntmds
18 Nov 22
Registration statement (foreign)
5:39pm
6-K
EX-10.1
xr04z3yu
18 Nov 22
Current report (foreign)
5:20pm
6-K
EX-10.1
eovup1f24ss g193
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
20-F
p5wl1wlvgcx
12 Aug 22
Annual report (foreign)
4:20pm
6-K
EX-1.1
m1psal3 00
26 Jul 22
Current report (foreign)
7:36am